CN115175908A - 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 - Google Patents

芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 Download PDF

Info

Publication number
CN115175908A
CN115175908A CN202180008854.2A CN202180008854A CN115175908A CN 115175908 A CN115175908 A CN 115175908A CN 202180008854 A CN202180008854 A CN 202180008854A CN 115175908 A CN115175908 A CN 115175908A
Authority
CN
China
Prior art keywords
group
formula
alkyl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180008854.2A
Other languages
English (en)
Other versions
CN115175908B (zh
Inventor
吕彬华
崔大为
刘连军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Original Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010033277.XA external-priority patent/CN113105448A/zh
Priority claimed from CN202010534664.1A external-priority patent/CN113801113A/zh
Priority claimed from CN202011563650.9A external-priority patent/CN114671866A/zh
Application filed by Suzhou Zelgen Biopharmaceutical Co Ltd, Shanghai Zelgen Pharmatech Co Ltd filed Critical Suzhou Zelgen Biopharmaceutical Co Ltd
Publication of CN115175908A publication Critical patent/CN115175908A/zh
Application granted granted Critical
Publication of CN115175908B publication Critical patent/CN115175908B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用。具体地，本发明化合物具有式(I)所示结构，本发明还公开了所述化合物的制备方法及其作为KRASG12C抑制剂的用途，对KRASG12C具有很好的选择性抑制作用且具有更好的药效学、药代动力学性能和更低的毒副作用。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180008854.2A 2020-01-13 2021-01-12 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 Active CN115175908B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010033277.XA CN113105448A (zh) 2020-01-13 2020-01-13 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN202010033277X 2020-01-13
CN2020105346641 2020-06-12
CN202010534664.1A CN113801113A (zh) 2020-06-12 2020-06-12 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN202011563650.9A CN114671866A (zh) 2020-12-25 2020-12-25 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN2020115636509 2020-12-25
PCT/CN2021/071331 WO2021143693A1 (zh) 2020-01-13 2021-01-12 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115175908A true CN115175908A (zh) 2022-10-11
CN115175908B CN115175908B (zh) 2024-07-23

Family

ID=76863562

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008854.2A Active CN115175908B (zh) 2020-01-13 2021-01-12 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Country Status (4)

Country Link
US (1) US20230118795A1 (zh)
EP (1) EP4092026A4 (zh)
CN (1) CN115175908B (zh)
WO (1) WO2021143693A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113801113A (zh) * 2020-06-12 2021-12-17 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
EP4194452A4 (en) * 2020-08-02 2024-08-21 Shanghai Zheye Biotechnology Co Ltd AROMATIC COMPOUND AND ITS USE IN ANTITUMOUS MEDICINES
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
CA3200164A1 (en) * 2020-11-26 2022-06-02 Qingxin Liu Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023165615A1 (en) * 2022-03-04 2023-09-07 I-Mab Biopharma Co., Ltd. Combination therapies comprising a kras inhibitor for the treatment of cancer
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113801113A (zh) * 2020-06-12 2021-12-17 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020279287A1 (en) * 2019-05-21 2021-12-16 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
WO2020239077A1 (zh) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 含氮杂环类衍生物调节剂、其制备方法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113801113A (zh) * 2020-06-12 2021-12-17 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113801113A (zh) * 2020-06-12 2021-12-17 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CN115175908B (zh) 2024-07-23
EP4092026A4 (en) 2024-03-06
WO2021143693A1 (zh) 2021-07-22
US20230118795A1 (en) 2023-04-20
EP4092026A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
CN115175908B (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN112694475A (zh) 环烷基类和杂环烷基类抑制剂及其制备方法和应用
KR20220119088A (ko) Kras 돌연변이체 단백질 억제제
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
CN115109078A (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN112778301A (zh) 四氢吡啶并嘧啶类抑制剂及其制备方法和应用
CN113105448A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115043842A (zh) 胺基取代双环类抑制剂及其制备方法和应用
CN114835719A (zh) 取代双环并芳杂环胺类抑制剂及其制备方法和应用
CN114835703A (zh) 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
CN114437077B (zh) 用作激酶抑制剂的化合物及其应用
CN114981273B (zh) 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN112867717B (zh) 用作激酶抑制剂的化合物及其应用
EP4234548A1 (en) Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
CN116217591A (zh) 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物
CN116390728A (zh) 喹唑啉衍生物及其制备方法和用途
CN113801113A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN115215869A (zh) 取代三环类抑制剂及其制备方法和应用
EP4143166A1 (en) Heterocyclic compounds as bet inhibitors
CN114671866A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115215844A (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
CN114380805A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN116867787A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant